Lindsay Grant, PhD, MPH (she/her/hers)

Senior Director, Evidence Generation Strategist Pneumococcal Vaccines
Pfizer Inc.

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Private Company)

Poster(s):

• (P-447) Differences in Invasive Pneumococcal Disease Clinical Presentations and Serotype Distribution among Children with and without Underlying Risk Factors
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-654) Demographic and Clinical Characteristics, by Pneumococcal Serotype, of Adults Hospitalized with Community Acquired Pneumonia in the United States
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-679) Invasive pneumococcal pneumonia: is bacteremia the appropriate indication of severity?
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1428) Real-World Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine among Adults 65-74, 75-84, and ≥85 Years of Age in the United States
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1429) Uptake and Series Completion with Pneumococcal Conjugate Vaccine by Social Determinants of Health among Children in the United States
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1464) Nasopharyngeal Colonization in South Texas Children less than 6 Years of Age with or without Lower Respiratory Tract Infections
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1571) Variability in Case-Ascertainment Methodology and Rates of Adult Invasive Pneumococcal Disease using a US Healthcare Claims Database
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET